Inoviq Ltd · ASX:IIQ
Inoviq — Shareholder Meeting (November 2025)
32 slides from Inoviq's shareholder meeting presentation, Nov 27, 2025
Slide 1: AGM Presentation
AGM Presentation For personal use only Next-generation exosome diagnostics and therapeutics 27 November 2025 ASX: IIQ
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) Actual results, performance or achievements could be significantly different from those based on information available to it as at the date of this presentation. This presentation expre
Slide 3: INOVIQ Overview | Next-generation diagnostics and therapeutics for cancer
INOVIQ Overview| Next-generation diagnostics and therapeutics for cancer For personal use only Financial snapshot (ASX:IIQ) Market capitalisation A$50.0m Proprietary exosome platform with multiple research, diagnostic and therapeutic applications Share price (26 November 2025) A$0.355 52-week H/L A$
Slide 4: Strategic pillars | Driving growth and value across our exosome business
Strategic pillars| Driving growth and value across our exosome business For personal use only 1 Research tools 2 Diagnostics 3 Therapeutics Exosome isolation tools for Exosome tests for screening, Exosome therapeutics biomarker discovery and liquid biopsies & companion to target and destroy diagnost
Slide 5: What are exosomes and how are they revolutionizing health care?
What are exosomes and how are they revolutionizing health care? For personal use only DIAGNOSTIC IIQ technology captures exosomes released from cancer cells and uses the messages to develop superior diagnostic tests Target cells internalize exosomes Exosomes are released from Exosome cargo alters ce
Slide 6: Why is IIQ's exosome isolation technology superior?
Why is IIQ’s exosome isolation technology superior ? For personal use only released exosomes in blood bulk isolation methods IIQ NET technology a heterogeneous mixture (competitor products) specific exosome isolation brain (EXO-NET technology) based on common physical properties • size * * * ** • ch
Slide 7: What are exosomes and how are they revolutionizing health care? (Therapeutics)
What are exosomes and how are they revolutionizing health care? For personal use only THERAPEUTICS CANCER CELL NORMAL CELL IIQ technology captures exosome released IIQ from cancer technology and instructs other cells, immune cells to reads the messages the to make exosomes that specifically target d
Slide 8: EXO-NET | Commercial progress with growing customers, revenue and pipeline
EXO-NET®| Commercial progress with growing customers, revenue and pipeline For personal use only Customer Acquisition Global distribution partner Promega Corporation delivering initial 80 revenues under Early Access Program building traction ahead of Full Catalogue Launch Q1 CY2026 of combination EX
Slide 9: EXO-OC | Commercialisation strategy
EXO-OC | Commercialisation strategy For personal use only Dual-path commercialisation strategy to maximise speed, access and value for patients, clinicians & investors Laboratory Developed Test In Vitro Diagnostic (LDT) (IVD) Laboratory partner Large diagnostics company Partner to offer testing serv
Slide 10: Exosome Diagnostics | Ovarian cancer screening requirements
Exosome Diagnostics| Ovarian cancer screening requirements For personal use only EXO-OC Ovarian Cancer Screening Test Understanding Test Performance An ovarian cancer screening test – for use in asymptomatic average-risk women (like the breast cancer screening program) Early detection means finding
Slide 11: Exosome Diagnostics | EXO-OC performance data
Exosome Diagnostics| EXO-OC performance data For personal use only EXO-OC Ovarian cancer screening test OC500 Study Ovarian cancer screening test for use by asymptomatic average-risk women (like the breast cancer screening program) Exceeds recommended test performance for ✓ Achieved 77% sensitivity
Slide 12: Exosome Diagnostics | Planned Studies
Exosome Diagnostics| Planned Studies For personal use only Clinical & Regulatory Advice underway EXO-OC Ovarian cancer screening test 2025 Ovarian cancer screening test Partnering with high-complexity CLIA lab for use by asymptomatic average-risk women LDT PATHWAY IVD PATHWAY (like the breast cancer
Slide 13: CAR-Exosomes | Next-gen cell-free therapy
CAR-Exosomes| Next-gen cell-free therapy For personal use only Off-the- shelf, allogenic Stabile & therapy Multiple easier to therapeutic manufacture applications • Platform technology with multiple therapeutic applications (CAR- EV therapy, Drug Delivery, Regenerative Medicine, Aesthetic Medicine,
Slide 14: CAR-Exosomes | Therapeutic development path
CAR-Exosomes| Therapeutic development path For personal use only EXO-ACE In Vivo CRO / Site First Patient CAR EV Isolation Studies Selection Dose 2023 2024 2025 2026 2027 2028 ` CAR-T / NK Cell In Vitro Process & Analytical Development, IND ‘Study May Development Studies CDMO selection, IND-enabling
Slide 15: Future Catalysts | Exosome platform driving growth and value across our pipeline
Future Catalysts| Exosome platform driving growth and value across our pipeline For personal use only Jul-25 Dec-25 Jun-26 Dec-26 EXO-NET • EXO-NET sales growth, collaborations & diagnostic partnering (research tools) EXO-OC ✓Commence clinical • Strategic partnering for LDT • Analytical and clinical
Slide 16: Summary | Positioned for growth
Summary| Positioned for growth For personal use only Leading exosome company Exosome research tools Clinical-stage EXO-OC with proven technology partnered, on-market and screening test targeting platform and best-in-class generating initial revenue significant unmet need in research tools, diagnosti
Slide 17: Contacts
Contacts For personal use only Dr Leearne Hinch BVMS MBA Prof Gregory Rice PhD MHA Chief Executive Officer Chief Scientific Officer e. lhinch@inoviq.com e. grice@inoviq.com Mark Edwards BAcc CA Dr Emma Ball PhD MBA GAICD CFO & Company Secretary Chief Commercial Officer e. medwards@inoviq.com e. ebal
Slide 18: Appendices
18 For personal use only Appendices
Slide 19: Glossary
Glossary For personal use only AUC area under the curve IVD in vitro diagnostic BC breast cancer KOL key opinion leader CA125 cancer antigen 125 biomarker (used in ovarian cancer) LDT laboratory developed test CA15-3 cancer antigen 15-3 biomarker (used in breast cancer) MIA in vitro multivariate ind
Slide 20: Board | Capital markets, healthcare and biotech experience
Board| Capital markets, healthcare and biotech experience For personal use only DAVID WILLIAMS MAX JOHNSTON PHILIP POWELL Non-Executive Chairman Non-Executive Director Non-Executive Director Experienced biotechnology director and Healthcare industry director and Healthcare industry director and inve
Slide 21: Leadership | Corporate, scientific, clinical and commercial expertise
Leadership| Corporate, scientific, clinical and commercial expertise use only MANAGEMENT DR LEEARNE HINCH BVMS MBA DR GREG RICE PhD MHA MARK EDWARDS BAcc CA EMMA BALL PhD MBA GAICD Chief Executive Officer Chief Scientific Officer CFO & Company Secretary Chief Commercial Officer Biotechnology CEO wit
Slide 22: Ovarian Cancer screening is a significant unmet need
Ovarian Cancer screening is a significant unmet need For personal use only Deadliest gynaecological cancer & 8th most 5-Year Survival following Diagnosis (UK)3 #1 common cancer in women 100% 95% 80% 60% 70% 325k New cases pa1 ~70% diagnosed at stage III or IV4 no approved 40% 45% test for early 20%
Slide 23: Ovarian Cancer in Major Markets
Ovarian Cancer in 9 Major Markets For personal use only Market Incidence Prevalence Eligible Population General Annual 1 (5-year) (45-74yo) Screening Addressable 11 Participation Population 2 China 61,060 180,870 282,713,102 51.4% 145,201,449 3 USA 21,179 68,388 60,689,385 75.7% 45,941,864 4 Japan 1
Slide 24: Diagnostic Deals | Liquid biopsy platforms
Diagnostic Deals| Liquid biopsy platforms For personal use only Upfront Milestones Total Deal Value Acquiror / Licensee Target / Licensor Date Deal Type Stage Technology (US$m) (US$m) (US$m) Various oncology screening, detection, monitoring and 1 2025 Acquisition Commercial N/A N/A $23,000 risk prof
Slide 25: CAR-Exosomes | Manufacturing & economics advantage
CAR-Exosomes| Manufacturing & economics advantage For personal use only CAR-exosomes restore the commercially-viable pharma model akin to monoclonals CAR-T Monoclonal Antibodies Average Price $509K1,2 $165K4 per dose per year Average COGS $170-200K3 1-25%5,6 per dose of market price COGS does not in
Slide 26: Triple Negative Breast Cancer | Unmet need for effective targeted therapies
Triple Negative Breast Cancer | Unmet need for effective targeted therapies For personal use only Percent of BC by Subtype4 2.3m Breast Cancer new cases pa1 HR-/HER2+ Unknown 4% 6% HR+/HER2+ 9% HR-/HER2- TNBC 15% TNBC is 10-15% of all breast cancer cases4 11% HR+/HER2- ~20% in women of 70% limited a
Slide 27: Breast Cancer in Major Markets | TNBC ~15% of cases
Breast Cancer in 9 Major Markets| TNBC ~15% of cases For personal use only Market Incidence Prevalence TNBC 1,2 3 (5-year) incidence USA 274,375 1,194,271 179,141 China 357,161 1,160,496 174,074 Japan 91,916 389,650 58,448 Germany 74,016 313,465 47,020 France 65,659 271,977 40,797 UK 58,756 253,839
Slide 28: Therapeutic Deals | Exosome & cell therapies
Therapeutic Deals| Exosome & cell therapies For personal use only Upfront Milestones Total Deal Value Acquirer / Licensee Target / Licensor Date Deal Type Stage Cell Source (US$m) (US$m) (US$m) 1 2025 Acquisition Phase 1 $350 $0 $350 in vivo CAR 2 2025 Acquisition Phase 1 $2,100 $0 $2,100 in vivo CA
Slide 29: SubB2M | neuCA15-3 breast cancer monitoring test
SubB2M| neuCA15-3 breast cancer monitoring test For personal use only SubB2M CA15-3 vs Leading IVD Test Sensitivity by 95% Specificity Monitoring Study Translation to LDT Single Lab ResearchDx IVD assay platform Partnering Future Diagnostics 2023 2024 2025 2026 ✓ Detected main breast cancer subtypes
Slide 30: SubB2M | neuCA15-3 breast cancer monitoring test
SubB2M| neuCA15-3 breast cancer monitoring test For personal use only Monitoring Study Translation to Strategic ResearchDx IVD assay platform Partnering Future Diagnostics 2023 2024 2025 2026 Analytical/Clinical Peer-reviewed Verification/ validation publication validation studies ResearchDx 30
Slide 31: References | Ovarian Cancer in Major Markets
References| Ovarian Cancer in 9 Major Markets For personal use only 1. United Nations, Data Portal, Population Division, 2024 data 2. The Lancet, Volume 55, Special Issue 101426, February 2025 3. Up-to-Date Breast, Cervical, and Colorectal Cancer Screening Test Use in the United States, 2021, CDC, h
Slide 32: References | Diagnostic & therapeutic deals
References| Diagnostic & therapeutic deals Diagnostic deals| Liquid biopsy platforms For personal use only 1. Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision, 20 November 2025 2. Freenome Announces Exclusive Agreement with Roche to Expand Technolog